Evidence map›Paper›PMID 37415744›Full record

ReviewOncology research2023

Tumor neoantigens: Novel strategies for application of cancer immunotherapy.

Hanyang Guan, Yue Wu, L U Li, Yabing Yang, Shenghui Qiu, Zhan Zhao, Xiaodong Chu, Jiashuai He, Zuyang Chen, Yiran Zhang and 3 more

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oncology research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Hanyang GuanDepartment of General Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, 510632, China.
Yue WuDepartment of Gynecology, Women's Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, Nanjing, 210004, China.
L U LiDepartment of Gastroenterology, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.
Yabing YangDepartment of General Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, 510632, China.
Shenghui QiuDepartment of General Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, 510632, China.
Zhan ZhaoDepartment of General Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, 510632, China.
Xiaodong ChuDepartment of General Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, 510632, China.
Jiashuai HeDepartment of General Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, 510632, China.
Zuyang ChenDepartment of General Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, 510632, China.
Yiran ZhangDepartment of General Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, 510632, China.
Hui DingDepartment of General Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, 510632, China.
Jinghua PanDepartment of General Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, 510632, China.
Yunlong PanDepartment of General Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, 510632, China.
First Affiliated Hospital of Jinan University · CNNanjing Maternity and Child Health Care Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neoantigen-targeted immunotherapy is a rapidly advancing field that holds great promise for treating cancer. The recognition of antigens by immune cells is a crucial step in tumor-specific killing, and neoantigens generated by mutations in cancer cells possess high immunogenicity and are selectively expressed in tumor cells, making them an attractive therapeutic target. Currently, neoantigens find utility in various domains, primarily in the realm of neoantigen vaccines such as DC vaccines, nucleic acid vaccines, and synthetic long peptide vaccines. Additionally, they hold promise in adoptive cell therapy, encompassing tumor-infiltrating cells, T cell receptors, and chimeric antigen receptors which are expressed by genetically modified T cells. In this review, we summarized recent progress in the clinical use of tumor vaccines and adoptive cell therapy targeting neoantigens, discussed the potential of neoantigen burden as an immune checkpoint in clinical settings. With the aid of state-of-the-art sequencing and bioinformatics technologies, together with significant advancements in artificial intelligence, we anticipated that neoantigens will be fully exploited for personalized tumor immunotherapy, from screening to clinical application.

Indexed as

Cancer VaccinesNeoplasmsAntigens, NeoplasmArtificial IntelligenceComputational BiologyHumansImmunotherapyAntigens, NeoplasmCancer VaccinesAdoptive T cell therapyChimeric antigen receptorImmunotherapyTumor vaccine

Identifiers

PMID37415744
PMCPMC10319592
OpenAlexW4381956111

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.